[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112014005487A2 - composições iodopovidona estáveis - Google Patents

composições iodopovidona estáveis

Info

Publication number
BR112014005487A2
BR112014005487A2 BR112014005487A BR112014005487A BR112014005487A2 BR 112014005487 A2 BR112014005487 A2 BR 112014005487A2 BR 112014005487 A BR112014005487 A BR 112014005487A BR 112014005487 A BR112014005487 A BR 112014005487A BR 112014005487 A2 BR112014005487 A2 BR 112014005487A2
Authority
BR
Brazil
Prior art keywords
compositions
povidone iodine
iodine compositions
stable
pvp
Prior art date
Application number
BR112014005487A
Other languages
English (en)
Inventor
Liang Bo
Michael Samson C
Stein Jason
Capriotti Joseph
Weiser Michael
Original Assignee
Foresight Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47883771&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014005487(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Foresight Biotherapeutics Inc filed Critical Foresight Biotherapeutics Inc
Publication of BR112014005487A2 publication Critical patent/BR112014005487A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A01N59/12—Iodine, e.g. iodophors; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo “composições iodopovidona estáveis” aqui são divulgadas composições contendo pvp-i, bem como os métodos de preparação de tais composições, que proporcionam estabilidade confiável para preparações pvp-i, incluindo preparações compreendendo pvp-i e um ou mais componentes adicionais.
BR112014005487A 2011-09-16 2012-09-14 composições iodopovidona estáveis BR112014005487A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535667P 2011-09-16 2011-09-16
PCT/US2012/055402 WO2013040347A1 (en) 2011-09-16 2012-09-14 Stable povidone-iodine compositions

Publications (1)

Publication Number Publication Date
BR112014005487A2 true BR112014005487A2 (pt) 2017-03-21

Family

ID=47883771

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014005487A BR112014005487A2 (pt) 2011-09-16 2012-09-14 composições iodopovidona estáveis

Country Status (16)

Country Link
US (1) US20150164939A1 (pt)
EP (2) EP2755477A4 (pt)
JP (3) JP6539444B2 (pt)
KR (2) KR20190099084A (pt)
CN (2) CN103889218A (pt)
AR (1) AR087857A1 (pt)
AU (2) AU2012308424B2 (pt)
BR (1) BR112014005487A2 (pt)
CA (1) CA2847364C (pt)
CL (2) CL2014000592A1 (pt)
CO (1) CO6930368A2 (pt)
EC (1) ECSP14013302A (pt)
MX (1) MX2014002679A (pt)
PE (1) PE20141676A1 (pt)
TW (4) TW201325601A (pt)
WO (1) WO2013040347A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103957922A (zh) * 2011-05-12 2014-07-30 前瞻生物治疗公司 含有甾体或非甾体抗炎药的稳定的聚维酮-碘组合物
CA2871778C (en) 2012-05-03 2022-09-13 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
KR102154880B1 (ko) 2012-05-03 2020-09-10 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
CA2900652C (en) 2013-02-15 2021-05-04 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
CN105189462B (zh) 2013-02-20 2017-11-10 卡拉制药公司 治疗性化合物和其用途
CA2928658A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2016344349B2 (en) * 2015-10-25 2022-05-19 Iview Therapeutics, Inc. Pharmaceutical formulations that form gel in situ
CA3036336A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10392399B2 (en) 2016-09-08 2019-08-27 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
JP6255134B1 (ja) * 2016-11-02 2017-12-27 ヴェローチェ・バイオファーマ・エルエルシー 耳炎の治療のための組成物および方法
CN110678207B (zh) * 2017-04-21 2024-08-02 德马利克治疗公司 碘组合物
CN110559175A (zh) * 2019-08-27 2019-12-13 陈文龙 一种结膜囊消毒溶液及其使用方法和装置
US20230181625A1 (en) * 2021-12-14 2023-06-15 Harrow Ip, Llc Method and composition for treating infectious conjunctivitis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3886268A (en) 1972-05-30 1975-05-27 Synergistics Iodophor-steroid compound pharmaceutical compositions
US4113857A (en) 1977-05-16 1978-09-12 The Purdue Frederick Company Process for the preparation of iodophor compounds and methods for stabilizing iodophor pharmaceutical compositions containing the same
US4954351A (en) * 1983-03-02 1990-09-04 Euroceltique S.A. Method of producing standardized povidone iodine preparations and such preparations
US4996048A (en) 1988-11-30 1991-02-26 Euroceltique, S.A. Stabilizing packaged iodophor and minimizing leaching of iodine through packaging
US5232692A (en) * 1989-04-28 1993-08-03 Research And Education Institute, Inc. Povidone-iodine neonatal ophthalmic antimicrobial prophylactic agent
US5126127A (en) 1991-07-16 1992-06-30 Euroceltique, S.A. Stabilized PVP-I solutions
IL135222A (en) * 2000-03-22 2005-06-19 Univ Ben Gurion Compositions containing molecular iodine
US20030207941A1 (en) * 2002-05-03 2003-11-06 Bingaman David P. Method of treating vascular endothelial growth factor mediated vascular disorders
US20060280809A1 (en) * 2005-06-14 2006-12-14 Leshchiner Adele K Anti-infective iodine based compositions for otic and nasal use
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US20090092574A1 (en) * 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
EP2229174A1 (en) * 2007-12-04 2010-09-22 Novagali Pharma S.A. Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders
US20090263345A1 (en) * 2008-01-28 2009-10-22 Foresight Biotherapeutics, Inc. Otic compositions for the treatment of infections of the internal and external ear in mammals
US20110054031A1 (en) * 2008-02-21 2011-03-03 Ista Pharmaceuticals, Inc. Ophthalmic NSAIDS as Adjuvants
CN102118973A (zh) * 2008-06-12 2011-07-06 前瞻生物治疗公司 一种眼科组合物中新的防腐剂替代物聚维酮碘
JP2010059058A (ja) * 2008-09-01 2010-03-18 Kowa Co 鎮痛・抗炎症剤含有外用剤
JP5410071B2 (ja) * 2008-10-07 2014-02-05 久光製薬株式会社 エステル化抑制剤及びエステル化抑制方法
PE20121498A1 (es) * 2009-12-15 2012-11-30 Foresight Biotherapeutics Inc Composiciones oftalmicas no irritantes de povidona-yodo
CN103957922A (zh) * 2011-05-12 2014-07-30 前瞻生物治疗公司 含有甾体或非甾体抗炎药的稳定的聚维酮-碘组合物

Also Published As

Publication number Publication date
AU2016204700B2 (en) 2018-03-22
CN103889218A (zh) 2014-06-25
AU2016204700A1 (en) 2016-07-21
KR20140077900A (ko) 2014-06-24
TW201808311A (zh) 2018-03-16
JP2014526514A (ja) 2014-10-06
AR087857A1 (es) 2014-04-23
WO2013040347A1 (en) 2013-03-21
US20150164939A1 (en) 2015-06-18
CN107595879A (zh) 2018-01-19
AU2012308424B2 (en) 2016-08-04
AU2012308424A1 (en) 2013-05-02
TW202126313A (zh) 2021-07-16
CL2017001952A1 (es) 2018-03-16
JP2018024689A (ja) 2018-02-15
TW202023575A (zh) 2020-07-01
CL2014000592A1 (es) 2014-11-03
CA2847364A1 (en) 2013-03-21
ECSP14013302A (es) 2014-05-31
MX2014002679A (es) 2014-04-25
EP2755477A4 (en) 2015-05-06
TW201325601A (zh) 2013-07-01
CA2847364C (en) 2020-08-25
JP6539444B2 (ja) 2019-07-03
KR20190099084A (ko) 2019-08-23
EP2755477A1 (en) 2014-07-23
JP2020007324A (ja) 2020-01-16
EP3556372A1 (en) 2019-10-23
CO6930368A2 (es) 2014-04-28
PE20141676A1 (es) 2014-11-06

Similar Documents

Publication Publication Date Title
BR112014005487A2 (pt) composições iodopovidona estáveis
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
EA201791717A1 (ru) Стабильные водные составы адалимумаба
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591455A1 (ru) Производные бензимидазолона в качестве ингибиторов бромодомена
EA201500394A1 (ru) Ингибиторы деметилаз гистонов
EA201500386A1 (ru) Пестицидные смеси, содержащие жасмоновую кислоту или её производное
EA201591632A1 (ru) Цитотоксические и антимитотические соединения и способы их применения
EA201890052A1 (ru) Регуляторы nrf2
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201170772A1 (ru) Органические соединения
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
EA201590586A1 (ru) Терапевтические наночастицы, включающие терапевтический агент, способы их получения и применения
BR112016029612A2 (pt) compostos de di-hidroisoquinolinona substituídos
BR112016015105A2 (pt) Conjugados var2csa-droga
EA201492011A1 (ru) Безводные фармацевтические составы для местного применения
BR112014015905A2 (pt) composição
BR112014028042A2 (pt) inibidores de nampt
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201590887A1 (ru) Композиция
BR112013028449A2 (pt) composições compreendendo partículas de hidrogel
EA201490846A1 (ru) Новые производные арилхинолина
MA33937B1 (fr) Composes pyrazole comme antagonistes du recepteur crth2
EA201690386A1 (ru) Соединения и композиции в качестве ингибиторов mek
BR112013012621A2 (pt) heterociclos microbicidas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: A01N 29/00

Ipc: A61K 31/192 (2006.01), A61K 31/196 (2006.01), A61K

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2687 DE 05-07-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.